Topically administered therapeutic agents for back of the eye disorders in various preclinical models (Rodrigues et al., 2018)
| Compound | Formulation | Preclinical Data | Reference |
|---|---|---|---|
| TG100801 | Solution | Murine CNV model and edema in rat | Doukas et al., 2008 |
| Pazopanib | Solution | Rat CNV model | Yafai et al., 2011, Singh et al., 2014 |
| Acrizanib | Suspension | Murine CNV | Adams et al., 2018 |
| Memantine | Solution | Drug levels in rabbit retina | Hughes et al., 2005 |
| Dorzolamide | Solution | Drug levels and carbonic anhydrase activity in corneal endothelial cells, ciliary body, lens epithelial cells, and retina in rabbit | Inoue et al., 2004 |
| Dexamethasone | Iontophoresis | Drug levels in retina and vitreous of rabbit | Ambati and Adamis, 2002 |
| Bevacizumab | Solution | Drug levels in iris/ciliary body, vitreous, retina/choroid, and plasma in rabbit | Ambati et al., 2000a |
| Anti-intercellular adhesion molecule-1 antibody | Solution by osmotic pump | Drug levels and VEGF-induced leukostasis in the choroid and retina in rabbit | Ambati et al., 2000b |
| 28-kD single-chain antibody fragment | Sodium caprate | Drug levels in vitreous in rabbit | Williams et al., 2005 |
| Bevacizumab | Annexin A5–based liposomes | Drug levels in retina of rat and rabbit | Davis et al., 2014 |
| Transforming growth factor β1 | Annexin A5–based liposomes | Drug levels in vitreous in rabbit | Platania et al., 2017 |
| Acidic fibroblast growth factor | CPP (TAT) | Ischemia reperfusion model in rat | Wang et al., 2010 |
| Calpain inhibitory peptide | CPP (TAT) | Drug levels in rabbit retina | Ozaki et al., 2015 |
| Green fluorescent protein | CPP (POD) | Drug levels in mouse cornea | Johnson et al., 2010 |
| Bevacizumab | CPP (R6) | Drug levels in vitreous and retina in rat and murine CNV model | de Cogan et al., 2017 |
CPP (R6), cell-penetrating peptide poly-arginine-6; POD, peptide of ocular delivery; TAT, transactivator of transcription.